These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21531324)

  • 1. High cut-off dialysis membranes: current uses and future potential.
    Gondouin B; Hutchison CA
    Adv Chronic Kidney Dis; 2011 May; 18(3):180-7. PubMed ID: 21531324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term serum proteomes are quite similar under high- and low-flux hemodialysis treatment.
    Hallbauer J; Kreusch S; Klemm A; Wolf G; Rhode H
    Proteomics Clin Appl; 2010 Dec; 4(12):953-61. PubMed ID: 21137035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should dialysis modalities be designed to remove specific uremic toxins?
    Baurmeister U; Vienken J; Ward RA
    Semin Dial; 2009; 22(4):454-7. PubMed ID: 19709001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis.
    Harding S; Provot F; Beuscart JB; Cook M; Bradwell AR; Stringer S; White D; Cockwell P; Hutchison CA
    Nephrol Dial Transplant; 2011 Apr; 26(4):1438. PubMed ID: 21406545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial.
    Haase M; Bellomo R; Baldwin I; Haase-Fielitz A; Fealy N; Davenport P; Morgera S; Goehl H; Storr M; Boyce N; Neumayer HH
    Am J Kidney Dis; 2007 Aug; 50(2):296-304. PubMed ID: 17660031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
    Pellicano R; Polkinghorne KR; Kerr PG
    Am J Kidney Dis; 2008 Jul; 52(1):93-101. PubMed ID: 18423807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large uremic toxins: an unsolved problem in end-stage kidney disease.
    Wolley MJ; Hutchison CA
    Nephrol Dial Transplant; 2018 Oct; 33(suppl_3):iii6-iii11. PubMed ID: 30281131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ways of intensification of hemodialysis therapy].
    Filiptsev PIa; Kirkhman VV; Timokhov VS
    Ter Arkh; 1988; 60(6):44-7. PubMed ID: 3206368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in solute removal by two high-flux membranes of nominally similar synthetic polymers.
    Ouseph R; Hutchison CA; Ward RA
    Nephrol Dial Transplant; 2008 May; 23(5):1704-12. PubMed ID: 18156455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renal replacement therapy by hemodialysis: an overview].
    Jacobs C
    Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is dialysis membrane type responsible for increased circulating adhesion molecules during chronic hemodialysis?
    Mrowka C; Heintz B; Sieberth HG
    Clin Nephrol; 1999 Nov; 52(5):312-21. PubMed ID: 10584995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Evolving Patterns of Uremia: Unmet Clinical Needs in Dialysis.
    Yu X
    Contrib Nephrol; 2017; 191():1-7. PubMed ID: 28910786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorbents in acute renal failure and end-stage renal disease: middle molecule and cytokine removal.
    Winchester JF; Silberzweig J; Ronco C; Kuntsevich V; Levine D; Parker T; Kellum JA; Salsberg JA; Quartararo P; Levin NW
    Blood Purif; 2004; 22(1):73-7. PubMed ID: 14732814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High cut-off and high-flux membrane haemodialysis in a patient with rhabdomyolysis-associated acute kidney injury.
    Albert C; Haase M; Bellomo R; Mertens PR
    Crit Care Resusc; 2012 Jun; 14(2):159-62. PubMed ID: 22697626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded Hemodialysis: A New Therapy for a New Class of Membranes.
    Ronco C; La Manna G
    Contrib Nephrol; 2017; 190():124-133. PubMed ID: 28535525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hemodialysis membranes: a historical perspective, current state and future prospect.
    Cheung AK; Leypoldt JK
    Semin Nephrol; 1997 May; 17(3):196-213. PubMed ID: 9165649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bench to bedside view of uremic toxins.
    Vanholder R; Baurmeister U; Brunet P; Cohen G; Glorieux G; Jankowski J;
    J Am Soc Nephrol; 2008 May; 19(5):863-70. PubMed ID: 18287557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Rationale for Expanded Hemodialysis Therapy (HDx).
    Hutchison CA; Wolley M
    Contrib Nephrol; 2017; 191():142-152. PubMed ID: 28910797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Place of Large Pore Membranes in the Treatment Portfolio of Patients on Hemodialysis.
    Van Biesen W; Vanholder R; Schepers E; Glorieux G; Dhondt A; Eloot S
    Contrib Nephrol; 2017; 191():168-177. PubMed ID: 28910800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.